13 years ago

Cell Medica Raises £17 Million to Advance Cancer Immunotherapy

  • Cell Medica, a London-based clinical stage cell therapeutics company, has secured £17 million in funding

  • The investment was led by Imperial Innovations Group plc, Invesco Perpetual, and the Cancer Prevention and Research Institute of Texas (CPRIT)

  • The Wellcome Trust will also become a shareholder in the business

  • Cell Medica intends to use the capital to continue development of its immune reconstitution cell therapies in Europe and launch new operations in Texas, focusing on cancer immunotherapy.

      • ProblemHealthcare

      "Many cancer patients who have undergone bone marrow transplants are susceptible to life-threatening viral infections. The current treatments are not always effective."

      Solution

      "Cell Medica has developed a technology that uses T-cells to prevent and treat life-threatening viral infections in leukaemia and lymphoma patients who have undergone bone marrow transplants."

      Covered on